News
Dr. Peter Marks, who has served since 2016 as the director of the Center for Biologics Evaluation and Research (CBER) within the FDA, said in a letter to Acting FDA Commissioner Sara Benner that ...
Dr. Peter Marks sent a letter to acting FDA Commissioner Sara Brenner on Friday saying that he would resign and retire by April 5 as director of the Center for Biologics Evaluation and Research.
FDA’s Center for Biologics Evaluation and Research is responsible for the safety and effectiveness of biological products, including vaccines, allergenic products, blood and blood products ...
The Wall Street Journal first reported news of Marks’ resignation. Both HHS and FDA did not respond to multiple requests by BioPharma Dive for comment. “I had the chance to work closely with ...
Dr. Peter Marks sent a letter to Acting FDA Commissioner Sara Brenner on Friday saying that he would resign and retire by April 5 as director of the Center for Biologics Evaluation and Research.
“He helped usher in scientific rigor and transparency into the FDA. And tonight, he is being pushed out,” Jha wrote on Friday. “Making the FDA dramatically weaker, less effective. This is ...
Dr. Peter Marks, who oversaw the FDA’s vaccine division as director of the Center for Biologics Evaluation and Research, submitted his resignation to acting FDA Commissioner Sara Brenner on Friday.
Dr. Peter Marks, a veteran official at the Food and Drug Administration (FDA) who helped establish the U.S. effort to rapidly develop Covid-19 vaccines, resigned on Friday. “It has become clear ...
Dr. Peter Marks sent a letter to Acting FDA Commissioner Sara Brenner on Friday saying that he would resign and retire by April 5 as director of the Center for Biologics Evaluation and Research.
Kennedy Jr. Marks, who has served as the FDA's vaccine chief since 2016, resigned in a letter sent to acting FDA Commissioner Sara Brenner. In it, he alleged Kennedy is not interested in "truth ...
Dr. Peter Marks sent a letter to Acting FDA Commissioner Sara Brenner on Friday saying that he would resign and retire by April 5 as director of the Center for Biologics Evaluation and Research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results